| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
2021 ASH annual meeting
|
del Pozo Martín, Yaiza
|
|
|
9 |
2 |
p. e92-e93
|
artikel
|
| 2 |
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group
|
Raje, Noopur S
|
|
|
9 |
2 |
p. e143-e161
|
artikel
|
| 3 |
Correction to Lancet Haematol 2021; 8: e410–21
|
|
|
|
9 |
2 |
p. e91
|
artikel
|
| 4 |
From residency training to professional life: which competencies and skills are most valued by haematologists in Brazil?
|
Barbosa, Ayla Cristina Nobrega
|
|
|
9 |
2 |
p. e95-e96
|
artikel
|
| 5 |
Individualised doses of anti-thymocyte globulin and immune recovery after allogeneic HSCT
|
Baron, Frédéric
|
|
|
9 |
2 |
p. e84-e86
|
artikel
|
| 6 |
Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial
|
Admiraal, Rick
|
|
|
9 |
2 |
p. e111-e120
|
artikel
|
| 7 |
KIR2DS1–HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials
|
Kaddu-Mulindwa, Dominic
|
|
|
9 |
2 |
p. e133-e142
|
artikel
|
| 8 |
Lakshmi Nayak: striving to contain the brain's deadliest killers
|
Cavanaugh, Ray
|
|
|
9 |
2 |
p. e97
|
artikel
|
| 9 |
Matchpoint: the game is not over for blast-phase chronic myeloid leukaemia
|
Rousselot, Philippe
|
|
|
9 |
2 |
p. e86-e87
|
artikel
|
| 10 |
Melflufen for multiple myeloma: a promise unfulfilled?
|
Kapoor, Prashant
|
|
|
9 |
2 |
p. e82-e84
|
artikel
|
| 11 |
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study
|
Schjesvold, Fredrik H
|
|
|
9 |
2 |
p. e98-e110
|
artikel
|
| 12 |
Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial
|
Copland, Mhairi
|
|
|
9 |
2 |
p. e121-e132
|
artikel
|
| 13 |
Reporting of trials with possible detrimental overall survival: a patient advocate perspective
|
Berger, Katherine
|
|
|
9 |
2 |
p. e94
|
artikel
|
| 14 |
Retinopathy associated with severe thrombocytopenia
|
Kaspi, Mathilde
|
|
|
9 |
2 |
p. e166
|
artikel
|
| 15 |
Risk stratified management approaches for smouldering multiple myeloma: clinical research becomes clinical practice
|
Lonial, Sagar
|
|
|
9 |
2 |
p. e162-e165
|
artikel
|
| 16 |
Thank you to our reviewers of 2021
|
The Editors of The Lancet Haematology,
|
|
|
9 |
2 |
p. e89-e90
|
artikel
|
| 17 |
The role of conferences in tackling inequalities
|
The Lancet Haematology,
|
|
|
9 |
2 |
p. e81
|
artikel
|
| 18 |
Using immunogenetics to inform immunotherapy of lymphoid malignancies
|
Vago, Luca
|
|
|
9 |
2 |
p. e88-e89
|
artikel
|
Tijdschrift beschrijving